Glatiramer acetate

PBAC's latest decision on Glatiramer acetate: Recommended (2022). Considered for Treatment of multiple sclerosis. The submission requested listing a new form of 40 mg glatiramer acetate pre-filled pen under the same circumstances as the PBS-listed 40 mg glatiramer pre-filled syringe.

Eligible population

Patients with multiple sclerosis treated with glatiramer acetate 40 mg

Therapy area

Neurology

Line of therapy

Not applicable

Evidence base

Cost-minimisation

Primary endpoint

Cost-minimisation

Comparator

glatiramer acetate 40 mg pre-filled syringe (GA PFS)

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated as submission assumed no differences in utilisation of healthcare resources between formulations.

Submission history

• Mar 2015: Recommended · Authority Required
• Jul 2017: Not recommended · Authority Required
• Mar 2021: Recommended · Authority Required
• Mar 2022: Recommended · Authority Required

Similar precedents

• Siponimod
  similarity 0.66
• Alemtuzumab
  similarity 0.65
• Ocrelizumab
  similarity 0.64
• Dimethyl fumarate
  similarity 0.64
• Natalizumab
  similarity 0.62
• Nabiximols
  similarity 0.63